Serum Institute to seek DCGI market nod for qHPV vaccine against cervical cancer

An official source aware of the development said if the government approves the SII's proposal, then it will save a significant amount of time to include the indigenously developed qHPV in the Universal Immunisation Programme.

Published On 2022-05-16 05:56 GMT | Update On 2024-02-16 06:01 GMT

New Delhi: The Serum Institute of India (SII) has sought the government's permission to manufacture and stockpile indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer after the completion of the phase 2/3 clinical trials to ensure its early availability in the country, official sources said on Sunday. The firm will soon seek market authorisation as...

New Delhi: The Serum Institute of India (SII) has sought the government's permission to manufacture and stockpile indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer after the completion of the phase 2/3 clinical trials to ensure its early availability in the country, official sources said on Sunday. The firm will soon seek market authorisation as well as a manufacturing licence from the Drugs Controller General of India (DCGI) for the vaccine, they said.

In a letter to the Union health ministry, Prakash Kumar Singh, director of Government and Regulatory Affairs at SII, is learnt to have said that the manufacturing of qHPV takes five-six months.

"We are ready to manufacture and stockpile qHPV at our own risk in view of early availability of this life-saving vaccine for the citizens of our country," an official source quoted Singh as having said in the letter.

The application mentions that every year, lakhs of women are diagnosed with cervical cancer and the death ratio is also very high. In India, cervical cancer ranks as the second most frequent cancer among women in the 15-44 age group.

"Currently, our country is fully dependent only on foreign manufacturers for vaccine against cervical cancer and the citizens of our country are bound to buy these vaccines at a very high price.

We have been working for more than five years under the leadership of our CEO Adar C Poonawalla for making available indigenous world-class vaccine against cervical cancer i.e. Quadrivalent Human Papillomavirus vaccine," Singh is learnt to have said in his letter.

"In line with the clarion call of our Prime Minister Narendra Modi (for) 'Making in India for the World' and 'Affordable Vaccines for All', we assure you that this year our qHPV vaccine will be available for the people of our country and the world at large," he said.

An official source aware of the development said if the government approves the SII's proposal, then it will save a significant amount of time to include the indigenously developed qHPV in the Universal Immunisation Programme.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Serum Institute to seek DCGI market nod for qHPV vaccine against cervical cancer

An official source aware of the development said if the government approves the SII's proposal, then it will save a significant amount of time to include the indigenously developed qHPV in the Universal Immunisation Programme.

Similar News